Tempus Open Link registry for cancer patients using Olivia platform

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational registry that uses the Olivia AI-enabled health platform to enable remote eConsent and enrollment for cancer patients. The platform collects retrospective and prospective data from multiple sources, including electronic health records, pathology/genomics, imaging, and patient-reported outcomes, into a single de-identified dataset. Sub-studies may be added to address specific research questions while Tempus maintains governance of the Olivia platform. Participation does not affect clinical care and does not involve investigational treatments. Data collection continues over time with longitudinal depth and multimodal integration.

Why it matters

Who can join: the full rules

ONCO-OLIVIA Registry:

Inclusion Criteria:

* Adults or children (all ages) with a pathologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) documented in the medical record; disease-specific cohorts may further define subtypes (e.g., stage, biomarker)
* Receiving care in the United States and/or U.S. Territories
* Participant (and/or legally authorized representative) is able and willing to provide electronic informed consent/permission and authorization via Olivia; with re-consent at age of eighteen if applicable
* Willing to authorize medical record retrieval under HIPAA Right of Access and/or TEFCA IAS
* Access to a smartphone, tablet, or web-enabled device for remote participation (directly or via caregiver) for eConsent and optional surveys

Exclusion Criteria:

* Not Applicable

Substudy OLV002: Pediatric Acute Myeloid Leukemia (pAML):

Inclusion Criteria:

* Receiving or have received care in the United States and/or U.S. Territories
* Participant (and/or legally authorized representative) is able and willing to provide electronic informed consent/permission and authorization via the platform; with re-consent at age of eighteen if applicable
* Legally authorized representative of participant who is deceased is able and willing to provide electronic informed consent/permission and authorization via the platform
* Willing to authorize medical record retrieval under HIPAA Right of Access and/or TEFCA IAS
* Access to a smartphone, tablet, or web-enabled device for remote participation (directly or via caregiver) for eConsent and cohort dependent PROs/surveys
* Pediatric patients with a confirmed diagnosis of Acute Myeloid Leukemia (AML) including the following AML subtypes per WHO/ICC classification: AML with core-binding factor rearrangements (AML-CBF), AML with inv(16) (AML-NV16), acute promyelocytic leukemia (APL), AML with KMT2A rearrangement (AML-KMT2A), AML with mutated NPM1 (AML-NPM1), AML with bZIP CEBPA mutations (AML-bZIP), AML with MECOM rearrangement

Exclusion Criteria:

\- Suspected but unconfirmed acute myeloid leukemia

Where it's running

• Tempus AI
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: Olivia Study Team
• Email: support@oliviahealth.ai
• Phone: 833-514-4187

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Urine samples from adults with solid cancers to explore chemistry linked to nearing end of life

  This study tests urine chemistry in adults with solid tumors to see if it reflects how close a patient is to death.

  Recruiting The Clatterbridge Cancer Centre NHS Foundation Trust · Liverpool, Merseyside · NCT07848997

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Leflunomide to prevent CMV reactivation after haploidentical stem cell transplant

  This study tests whether leflunomide can prevent CMV reactivation in adults undergoing haploidentical hematopoietic stem cell transplantation.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 2 other locations · NCT07709013

• MK-1045-006: testing a new treatment for B-cell cancers like CLL and SLL

  This trial will test MK-1045 in people with relapsed or treatment‑refractory CLL/SLL to see if it’s safe and how well it works.

  Recruiting at 8 sites Phase 2 Merck Sharp & Dohme LLC · Medellín, Antioquia and 7 other locations · NCT07709000

• Metronomic low-dose gemcitabine, mitomycin C, and thalidomide for advanced solid tumors

  This phase II trial tests a low-dose, continuously given combo of gemcitabine, mitomycin C, and thalidomide in adults with advanced solid tumors to see if it helps control the disease.

  Recruiting Phase 2 Sarcoma Oncology Research Center, LLC · Santa Monica, California · NCT07671534

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.